These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3778761)

  • 1. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.
    Molitoris BA; Alfrey AC; Alfrey PS; Miller NL
    Kidney Int; 1988 Jul; 34(1):98-101. PubMed ID: 3172641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine induced aluminium removal in haemodialysis.
    Bonal J; Montoliu J; Löpez Pedret J; Bergadä E; Andrew L; Bachs M; Revert L
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():366-70. PubMed ID: 3991524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients.
    Delmez J; Weerts C; Lewis-Finch J; Windus D; Slatopolsky E
    Am J Kidney Dis; 1989 Apr; 13(4):308-11. PubMed ID: 2705449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients.
    McCarthy JT; Milliner DS; Schmidt DF; Schniepp BJ; Kurtz SB; Johnson WJ
    Kidney Int; 1988 Dec; 34(6):804-8. PubMed ID: 3210542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
    Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
    Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron removal by desferrioxamine during haemodialysis: in vitro studies.
    Müller-Wiefel DE; Vorderbrügge U; Schärer K
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():377-81. PubMed ID: 3991526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immobilized desferrioxamine (DFO) for the extracorporeal removal of aluminum.
    Anthone S; Ambrus CM; Horvath C; Kalghatgi K
    ASAIO Trans; 1987; 33(3):744-8. PubMed ID: 3676012
    [No Abstract]   [Full Text] [Related]  

  • 15. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
    Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brain.
    Yokel RA; Lidums V; Ungerstedt U
    Toxicology; 1991 Mar; 66(3):313-24. PubMed ID: 2011855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant iron and aluminum mass transfer following deferoxamine infusion during hemofiltration.
    Canavese C; Salomone M; Pacitti A; Mangiarotti G; Thea A; Dogliani M; Serra A
    Am J Kidney Dis; 1991 Feb; 17(2):179-84. PubMed ID: 1992660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
    Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
    Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.